•  
  •  



Product Information

  • Zolpimist® (zolpidem tartrate) is a patented, FDA approved bioequivalent version of the market leading sleep aid, Ambien® in an oral spray formulation.

  • Zolpidem is the most commonly prescribed agent for the treatment of insomnia with a market share of approximately 70%, with over 1.2 billion zolpidem tablets prescribed in 2010 in the US.

  • Zolpimist® is engineered to outperform the oral tablets

  • Using a proprietary and patented technology we deliver the drug as a fine mist into the mucosal membranes lining the cheeks in the mouth (buccal delivery). This mode of delivery offers some very clear advantages as compared to other delivery methods:

  • Fast onset of action; Zolpimist® induces sleep three times faster than oral tablets – 10 minutes as compared to 30 – 40 minutes for oral tablets.

  • No food effect that mitigates the efficacy of other zolpidem products


Zolpimist® (zolpidem oral spray)

  • Approved by FDA December 2008; currently being sold by Hi-Tech Pharmacal ("HITK" Nasdaq), licensed from NovaDel Pharma.

  • Zolpidem, the active ingredient in both Ambien® (Sanofi-Aventis) and Zolpimist®, is the leading sleep aid on the market with an approximate market share of 70%.

  • Zolpimist® is a patented product developed and designed to provide patients with faster onset of sleep as demonstrated in various clinical studies.

  • Two dosages have been approved

    •  5mg – one spray

    • 10mg – two sprays
​​



​​